

**Amendments to the Claims**

Please add new Claim 14. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

- 1) (Original) A method of inhibiting the proliferation of a eukaryotic cell whose growth is stimulated by  $\beta$ -catenin-mediated gene transcription, comprising contacting said cell with:
  - a) a non-endogenous source of RXR nuclear receptor protein, and
  - b) a therapeutically effective amount of an agonist of said RXR protein.
- 2) (Original) The method of claim 1 wherein said RXR agonist is not an agonist of an RAR nuclear receptor.
- 3) (Original) The method of claim 2 wherein said RXR protein is an RXR $\alpha$  protein.
- 4) (Original) The method of claim 1 wherein said RXR protein is expressed within said cell by an expression vector.
- 5) (Original) The method of claim 4 wherein said expression vector is a viral expression vector.
- 6) (Original) The method of claim 5 wherein said expression vector is selected from the group consisting of an adenovirus-derived expression vector, an adeno associated virus-derived expression vector and a retrovirus-derived expression vector.
- 7) (Original) The method of claim 6 wherein said expression vector is an adenovirus-derived expression vector.

- 8) (Original) The method of claim 4 in which said expression vector is injected into said cell.
- 9) (Original) The method of claim 1 in which said cell is a colon cell and said non-endogenous source of RXR protein is provided to said cell by means of oral or rectal administration.
- 10) (Original) The method of claim 9 in which said RXR ligand is contacted with said cell by systemic administration.
- 11) (Original) The method of claim 1 wherein said cell is a cancer cell.
- 12) (Original) The method of claim 11 wherein said cancer cell is a colon cancer cell.
- 13) (Original) A method for determining whether a test compound is an RXR agonist comprising administering said test compound to a cell which expresses RXR and  $\beta$ -catenin, and determining whether  $\beta$ -catenin is degraded in response to the addition of said test compound, wherein the degradation of said  $\beta$ -catenin indicates that said test compound is an RXR agonist.
- 14) (New) A method of inhibiting the proliferation of a eukaryotic cell whose growth is stimulated by  $\beta$ -catenin-mediated gene transcription, comprising contacting said cell with:
  - a) a non-endogenous source of RXR nuclear receptor protein, and
  - b) a therapeutically effective amount of an agonist of said RXR protein, wherein the agonist is identified by a method comprising administering a test compound to a cell which expresses said RXR nuclear receptor protein and  $\beta$ -catenin, and determining whether  $\beta$ -catenin is degraded in response to the addition of said test compound, wherein the degradation of said  $\beta$ -catenin indicates that said test compound is an RXR agonist.